Immunohistochemical Assay Variability and Human Epidermal Growth Factor Receptor 2 (HER2)-Low Breast Cancer Detection: A Laboratory Comparison in the Netherlands.

Zeynep E Kain¹, Emma Schuurman², Ximena Baez-Navarro³, Henrik Høeg⁴, Prasanth Kanneganti⁵, Nils 't Hart², Carolien H M van Deurzen³

¹Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: z.kain@erasmusmc.nl.

²Department of Pathology, Isala, Zwolle, the Netherlands.

³Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands.

⁴Visiopharm A/S, Hørsholm, Denmark.

⁵Boston Cell Standards Inc, Boston, Massachusetts.

PubMed DOI

Abstract

PURPOSE: HER2-low breast cancer has gained clinical relevance owing to the efficacy of trastuzumab deruxtecan. However, variability in detecting low HER2 expression may affect patient eligibility. This nationwide study in the Netherlands evaluated the variability in HER2 immunohistochemistry (IHC) assays at low expression levels and compared this with the reported HER2-low rates across pathology l…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.